Nicholas Hertz | BiotechTV

top of page

BIO 2026: Montara is trying to open more CNS treatment possibilities by using one drug that blocks a target-specific drug’s activity in the periphery in combo with a brain active and concentrated one

CEO Nicholas Hertz describes this approach, which was recently made famous through the success of Karuna. Andrew Miller, a founder of Karuna, recently joined Montara's board. Coverage brought to you by

Company News

1 day ago

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

10x Genomics delivers powerful, reliable tools that fuel scientific discoveries and drive exponential progress to master biology to advance human health. Cited in more than 10,000 research papers, our innovative single cell, spatial, and in situ technologies enable discoveries across oncology, immunology, neuroscience, and more.

Our talented, dedicated science professionals have a distinguished record of creating innovative instruments, reagents, and software that analyze biological systems at a resolution that matches the complexity of biology.

Learn more

bottom of page

BIO 2026: Montara is trying to open more CNS treatment possibilities by using one drug that blocks a target-specific drug’s activity in the periphery in combo with a brain active and concentrated one

Follow BiotechTV

Sponsors

Sponsor Spotlight